Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Musculoskeletal  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Acute Myeloid Leukemia Clinical Trials

A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (556) clinical trials

Alternative Splicing and Leukemia Initiating Cells

Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukaemia (AML) are frequent. It have been shown that some splicing variants had a prognostic value in AML. AML are characterized by their propensity to relapse because of the persistence of leukaemia initiating cells (LICs). The aim of this ...

Phase N/A

Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

The type of AML being studied in this clinical trial is known as FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) positive AML. This type of AML has an alteration (or mutation) in genes, which may associated with high risk of relapse after conventional chemotherapy and hence an extremely poor ...

Phase

Sorafenib to Treat FLT3-ITD AML

It is a prospective, non-interventional, open-label study, in order to observe the safety and response in FLT3-ITD mutation positive AML patients who receiving sorafenib as induction, consolidation, salvage, maintenance or alleviative treatment. The duration of the study from June 2014 through May 2019, with the recruitment duration from June 2014 ...

Phase N/A

Study of Palbociclib in MLL-rearranged Acute Leukemias

Diagnosis: Acute myeloid leukemia; Acute lymphoblastic leukemia Age 18 years, no upper age limit Study drug: Palbociclib Phase Ib/IIa, open-label Phase Ib: Based on previous experience with 125 mg palbociclib once daily for 21 days followed by 7 days of rest in patients with breast cancer, liposarcoma, non-small cell lung ...

Phase

Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia

This is an open label study to assess the suitability of CPX-351 as first intensive therapy in elderly (age 60 years) patients with AML. Patients may have received prior AML treatment with non-intensive regimens, e.g. hypomethylating agents, low dose Ara C or lenolidomide, but may not have received intensive AML ...

Phase

Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia

The investigators are undertaking a parallel group, multicentre, randomized controlled trial of 80 adults with chemotherapy-induced thrombocytopenia from 8 medical centers in China. AML patients with PLT count <3010^9/L during the previous cycle of chemotherapy are randomized into two groups that one receives rhTPO at 1.0g/kgd subcutaneously for 7~14 consecutive ...

Phase

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Primary AML includes CBF(Core binding factor)-AML and non-CBF-AML. After the second course of therapy, CBF-AML are stratified into two risk groups: low-risk children are defined as those with CR after MAE or CAG, high-risk children are those with CR after consolidation course 1 or IAE. Non-CBF-AML patients in remission are ...

Phase N/A

Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations

The main trial is a double-blinded, placebo-controlled, randomized, phase III, multi-center trial in adult patients with relapsed or refractory AML harboring an activating FLT3 mutation as defined in the inclusion /exclusion criteria. An initial open label dose-finding run-in phase I of the study will be performed administering the study drug ...

Phase

Hematopoietic Stem Cell Microtransplantation for in AML

Despite allogeneic HSCT is the only curative therapy for AML, some patients can not receive transplantation due to intolerance of transplant-related toxicity or unwillingness of HSCT. For these patients, microtransplantation seems an optional therapy. However, the efficacy still remain unclear.

Phase N/A

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a blood disorder and kidney disease. The aim ...

Phase N/A